Why is the presence of autoantibodies against GAD associated with a relatively slow progression to clinical diabetes?
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
---|---|
Enthalten in: |
Diabetologia - 63(2020), 8 vom: 11. Aug., Seite 1665-1666 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ziegler, Anette-Gabriele [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 11.08.2021 Date Revised 26.11.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1007/s00125-020-05175-8 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM310337208 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM310337208 | ||
003 | DE-627 | ||
005 | 20231225135857.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s00125-020-05175-8 |2 doi | |
028 | 5 | 2 | |a pubmed24n1034.xml |
035 | |a (DE-627)NLM310337208 | ||
035 | |a (NLM)32451571 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ziegler, Anette-Gabriele |e verfasserin |4 aut | |
245 | 1 | 0 | |a Why is the presence of autoantibodies against GAD associated with a relatively slow progression to clinical diabetes? |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 11.08.2021 | ||
500 | |a Date Revised 26.11.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
650 | 4 | |a Letter | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Autoantibodies |2 NLM | |
650 | 7 | |a Insulin |2 NLM | |
650 | 7 | |a Nerve Tissue Proteins |2 NLM | |
650 | 7 | |a SLC30A8 protein, human |2 NLM | |
650 | 7 | |a TSPAN7 protein, human |2 NLM | |
650 | 7 | |a Tetraspanins |2 NLM | |
650 | 7 | |a Zinc Transporter 8 |2 NLM | |
650 | 7 | |a PTPRN protein, human |2 NLM | |
650 | 7 | |a EC 3.1.3.48 |2 NLM | |
650 | 7 | |a Receptor-Like Protein Tyrosine Phosphatases, Class 8 |2 NLM | |
650 | 7 | |a EC 3.1.3.48 |2 NLM | |
650 | 7 | |a Glutamate Decarboxylase |2 NLM | |
650 | 7 | |a EC 4.1.1.15 |2 NLM | |
650 | 7 | |a glutamate decarboxylase 2 |2 NLM | |
650 | 7 | |a EC 4.1.1.15 |2 NLM | |
700 | 1 | |a Bonifacio, Ezio |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Diabetologia |d 1966 |g 63(2020), 8 vom: 11. Aug., Seite 1665-1666 |w (DE-627)NLM000017035 |x 1432-0428 |7 nnns |
773 | 1 | 8 | |g volume:63 |g year:2020 |g number:8 |g day:11 |g month:08 |g pages:1665-1666 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00125-020-05175-8 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 63 |j 2020 |e 8 |b 11 |c 08 |h 1665-1666 |